Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Journey Medical (DERM) Debt to Equity (2020 - 2025)

Journey Medical (DERM) has disclosed Debt to Equity for 6 consecutive years, with $0.97 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Debt to Equity fell 46.35% year-over-year to $0.97, compared with a TTM value of $0.97 through Sep 2025, down 46.35%, and an annual FY2024 reading of $1.24, up 72.53% over the prior year.
  • Debt to Equity was $0.97 for Q3 2025 at Journey Medical, down from $1.3 in the prior quarter.
  • Across five years, Debt to Equity topped out at $1988.4 in Q2 2023 and bottomed at -$1.28 in Q3 2021.
  • Average Debt to Equity over 5 years is $125.11, with a median of $1.15 recorded in 2024.
  • The sharpest move saw Debt to Equity skyrocketed 467596.73% in 2023, then tumbled 99.91% in 2024.
  • Year by year, Debt to Equity stood at $0.02 in 2021, then skyrocketed by 6843.66% to $1.34 in 2022, then tumbled by 46.42% to $0.72 in 2023, then surged by 72.53% to $1.24 in 2024, then decreased by 21.64% to $0.97 in 2025.
  • Business Quant data shows Debt to Equity for DERM at $0.97 in Q3 2025, $1.3 in Q2 2025, and $1.16 in Q1 2025.